SCHEMBL28635462

SCHEMBL28635462

CS(=O)(=O)c1ccc2c(c1)c1cc(Br)ccc1n2CC(O)CNc1ccccc1

nearest known ligand 0.77

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
DNM1 Q05193 8/20 0.77
MAPT P10636 4/20 0.48
KMT2A Q03164 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 2/20 0.48
ALDH1A1 P00352 2/20 0.48
KDM4E B2RXH2 1/20 0.48
HPSE Q9Y251 1/20 0.48
HTT P42858 2/20 0.47
NPSR1 Q6W5P4 2/20 0.47
PER2 O15055 3/20 0.46
CRY1 Q16526 3/20 0.46
CRY2 Q49AN0 3/20 0.46
TSPO P30536 1/20 0.45
RAD52 P43351 1/20 0.44
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30897307 1.00 DNM1 (0.77) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL29391692 0.88 DNM1 (1.00) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL410147 0.88 DNM1 (1.00) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL29351340 0.88 DNM1 (1.00) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL28641677 0.88 TSPO (0.64) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL30897308 0.88 TSPO (0.64) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL20334192 0.82 DNM1 (0.88) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL14689975 0.81 DNM1 (0.80) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL410692 0.81 DNM1 (0.85) DNM1MAPTKMT2ASMN1; SMN2MEN1
SCHEMBL406986 0.79 DNM1 (0.78) DNM1MAPTKMT2ASMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402444-B Carbazole compound and application thereof in preparation of medicines for treating fatty liver and type 2 diabetes and other metabolic related diseases 上海欧坤生物医药科技有限公司 2024-05-03 CN claimed
CN-113402444-A Carbazole compound and application thereof in preparation of medicines for treating metabolic related diseases such as fatty liver and type 2 diabetes 上海欧坤生物医药科技有限公司 2021-09-17 CN claimed
CN-113402444-B Carbazole compound and application thereof in preparation of medicines for treating fatty liver and type 2 diabetes and other metabolic related diseases 上海欧坤生物医药科技有限公司 2024-05-03 CN disclosed
CN-113402444-A Carbazole compound and application thereof in preparation of medicines for treating metabolic related diseases such as fatty liver and type 2 diabetes 上海欧坤生物医药科技有限公司 2021-09-17 CN disclosed